SCHEMBL4165767

SCHEMBL4165767

Cc1cc(Nc2cnc(-c3ccc(Cl)c(OCc4ccccc4)c3)c(N)n2)n[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGAM O43451 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ SI P14410 1/20 0.44
▸ MGAM2 Q2M2H8 1/20 0.44
▸ AURKA O14965 5/20 0.41
▸ PAK4 O96013 3/20 0.41
▸ AURKB Q96GD4 3/20 0.41
▸ RET P07949 2/20 0.41
▸ ABL1 P00519 2/20 0.41
▸ KDR P35968 2/20 0.41
▸ DAPK3 O43293 1/20 0.41
▸ JAK2 O60674 1/20 0.41
▸ LCK P06239 1/20 0.41
▸ FYN P06241 1/20 0.41
▸ CSF1R P07333 1/20 0.41
▸ IGF1R P08069 1/20 0.41
▸ PDGFRB P09619 1/20 0.41
▸ FGFR1 P11362 1/20 0.41
▸ FLT1 P17948 1/20 0.41
▸ LTK P29376 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4171086 0.86 NPC1 (0.41) GAAAURKAPAK4AURKBRET
SCHEMBL4161611 0.84 IGF1R (0.40) AURKARETKDRIGF1RFLT3
SCHEMBL4168909 0.82 IKBKB (0.46) AURKAPAK4AURKBRETJAK2
SCHEMBL4169281 0.81 MEN1 (0.43) AURKAPAK4AURKBRETKDR
SCHEMBL4170524 0.81 MEN1 (0.38) GAAAURKAPAK4RETKDR
SCHEMBL4168663 0.80 AURKB (0.43) AURKAPAK4AURKBRETJAK2
SCHEMBL13663504 0.79 AURKA (0.44) AURKAPAK4AURKBRETABL1
SCHEMBL4179012 0.78 MEN1 (0.46) AURKAPAK4RETJAK2GSK3B
SCHEMBL4298197 0.78 DHFR (0.46) GAAAURKAAURKBRETJAK2
SCHEMBL4166686 0.77 DHODH (0.40) AURKAPAK4AURKBRETJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2009-10-29 — — US claimed
WO-2009089042-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2009-07-16 — — WO claimed
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2009-10-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH MAP3K1, MAP3K15, MAP3K5 MGAM 4274/4885GAA 3207/4885SI 3810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback